Managing Partner – Sector Advisory — Implantable-Devices Division

The mandate

An international advisory partnership has strong medical-technology relationships but no coherent implantables practice. Strategy teams advise boards on growth and transactions; regulatory specialists address technical files; operations teams support plants; and leadership advisers work separately with executives. Clients increasingly need joined-up answers on portfolio renewal, evidence investment, product safety, manufacturing transfer and post-acquisition integration. The firm often sees only one part of the decision and loses accountability when implementation begins.

The partner council has approved a Munich-centred sector practice with a deliberately narrow proposition. It will focus on high-consequence implantable-device decisions where clinical evidence, design control, quality, supply and economics cannot be separated. The objective is not to create another broad medtech label or a referral layer among existing practices. It is to assemble credible teams, lead difficult board decisions and remain accountable through execution.

The Managing Partner – Sector Advisory will define, originate and lead the practice. The broader perimeter includes approximately 875 partners, professionals and material affiliates across regional practices. The incoming leader must build collaboration without claiming every relevant client or expert. Commercial success will be judged on repeatable client outcomes, quality and partner development as well as fees.

The role is on site in Munich, reports to the Global Managing Partner and regional partner council and is advisory in structure. European and international client travel is substantial. Independence, conflicts, patient impact and technical limitations must be addressed before the firm accepts work, especially where it serves investors, manufacturers and counterparties in the same category.

Why this seat is open

This is a new role created after a strategic review of lost and fragmented medtech assignments. Existing partners retain their practices and account responsibilities. The council wants an external leader with implantables depth and cross-functional advisory credibility rather than appointing a coordinator whose authority depends on internal referrals.

What you will own

• Define the implantables proposition, priority client situations, evidence standard and work the firm will explicitly decline or refer.
• Originate and lead board engagements involving portfolio renewal, clinical and regulatory strategy, technical diligence, remediation, manufacturing transfer and operating-model change.
• Build integrated teams from clinical, regulatory, quality, engineering, operations, commercial, finance and leadership disciplines under one accountable partner.
• Develop a practice P&L and talent system across the wider 875-person and affiliate perimeter, with transparent contribution, investment and concentration.
• Establish independent technical and quality review for recommendations capable of affecting patient safety, regulatory evidence or release of material capital.
• Manage conflicts among investors, manufacturers, suppliers, notified bodies and transaction parties and restructure or decline work when safeguards are inadequate.
• Create reusable methods and evidence without transferring confidential client data or pretending that one implant category’s answer applies to another.
• Develop partners and experts able to originate and deliver independently, reducing reliance on the Managing Partner’s relationships.

The first 12 months

• Days 1–90: Review current work, losses, conflicts and capability; interview selected clients and technical leaders; and choose three priority offers. Establish quality and independence rules and lead one lighthouse assignment where the initial commercial or portfolio thesis requires technical and patient-risk challenge.
• Months 4–9: Appoint the core partner and expert team, integrate pipeline and account planning and win at least two additional cross-functional mandates. Build diagnostic and decision methods for the chosen offers and recruit gaps in clinical evidence, implant engineering or quality remediation.
• Months 10–12: Deliver referenceable client outcomes, demonstrate profitable growth and a diversified pipeline and show that other partners can lead assignments. Close any offer that produces generic activity, review conflicts and quality outcomes with the council and approve the next investment and succession plan.

What the board will measure

• Profitable fee growth from defined implantables offers, separated from work merely reclassified from existing practices.
• Client decisions and operating outcomes changed by integrated clinical, technical, quality and economic evidence.
• Repeat and referral work with acceptable client, investor and originating-partner concentration.
• Quality and independence performance, including recommendations challenged, engagements redesigned and work declined.
• Partner and expert bench strength, with assignments originated and led without dependence on the incoming Managing Partner.
• Practice economics that reflect real senior and technical effort and do not conceal unfunded affiliate or specialist contribution.

The person

You are a managing partner, senior partner, global medtech practice leader or senior implantables executive with at least 28 years of experience. You have led a practice, P&L or advisory perimeter of at least EUR 250 million and influenced 500 or more professionals and client executives. Personal responsibility for board decisions and implementation is required.

You understand implantables beyond market size. You can discuss clinical evidence, design changes, biocompatibility, sterilisation, post-market signals, manufacturing transfer and hospital adoption at decision level. You have advised or operated through a product remediation or portfolio choice and can show where technical evidence changed the economic answer.

The firm will consider leaders from consulting, professional services, specialised regulatory or quality advisory, investment operating teams or industry. Operating candidates must demonstrate client origination and advisory judgement; consulting candidates must demonstrate technical and implementation accountability. A portable contact list will not compensate for weak sector depth or conflicted relationships.

The role is based in Munich with substantial travel. The Managing Partner must work inside collaborative partnership economics, invest in successors and accept independent review. Candidates must honour current obligations and may not bring restricted client, pricing or method information into the process.

Compensation and terms

The indicative base or drawings range is EUR 410,000–590,000, with annual incentive and long-term participation under the partnership framework. Measures will combine client outcomes, profitable growth, quality, firm-wide collaboration and successor development. Partnership capital, deferred awards, notice and restrictions will be reviewed during reciprocal diligence.

Confidentiality

The firm, partners, clients and live assignments are confidential. Identifying information will follow only after mutual relevance and appropriate protections are established. Candidates must not disclose restricted client or employer information or solicit business connected to a current mandate.

Each response must contain no more than 49 words.